Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb (or BMS), joins a16z Bio + Health general partner Jorge Conde.
Together, they talk about how AI could transform drug discovery and development at a large biopharma company—and how a company might have to adapt to harness AI; modalities they’re excited about; and Greg’s do’s and don’ts for startups looking to partner with a company like BMS.
AI in Pharmaceutical R&D with Kim Branson
Unleashing CAR T with Carl June
Longevity as a Health Asset with Tom Hale
The Power of Drug Discovery with Philip Tagari
AI-Enabled Continuity of Care with Ed and Todd Park
Grand Challenges in Healthcare AI with Vijay Pande and Julie Yoo
Behind the Buy: Payors and Providers on AI Adoption
Biotech Revolution with Software Engineering Daily
Dark Genome Hunting with Rosana Kapeller and Marty Taylor
DNA as Data Storage with Vijay Pande
The Most Interesting Healthcare Companies You've Never Heard Of with Julie Klapstein
CRISPR by Design with Benjamin Oakes
Metrics for a Complex Machine with Josh Clemente
Transitioning From Gymnast to Investor with Aly Raisman
Finding PMF in Healthcare (After Tasting it Elsewhere) with Eren Bali and Max Cohen
IRA, AI Regulation, and the Future with Joe Grogan
Drag & Drop Genome Editing
Past, Present, and Future of AI with Vijay Pande
Fireside Chat with Sean Duffy
Create your
podcast in
minutes
It is Free